Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

Lana Hamieh, MD
Published: Friday, Jan 13, 2017



Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma (RCC).

Poor-risk patients are only occasionally enrolled in clinical trials, making them less likely to be characterized, explains Hamieh. A comprehensive analysis of poor-risk patients, according to Memorial Sloan Kettering Cancer Center, the International Metastatic Database Consortium, and the Hughes risk criteria, was collected in a clinical trials database.

Approximately 4,700 poor-risk patients receiving targeted treatment in phase II and III clinical trials were selected from the database. Using the poor-risk criteria, patients were then separated into either the total cohort of patients or a subset of patients who remained on therapy for more than 12 months. With the primary endpoint being overall survival, the patients were evaluated for overall response rate and toxicities.
 
SELECTED
LANGUAGE


Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma (RCC).

Poor-risk patients are only occasionally enrolled in clinical trials, making them less likely to be characterized, explains Hamieh. A comprehensive analysis of poor-risk patients, according to Memorial Sloan Kettering Cancer Center, the International Metastatic Database Consortium, and the Hughes risk criteria, was collected in a clinical trials database.

Approximately 4,700 poor-risk patients receiving targeted treatment in phase II and III clinical trials were selected from the database. Using the poor-risk criteria, patients were then separated into either the total cohort of patients or a subset of patients who remained on therapy for more than 12 months. With the primary endpoint being overall survival, the patients were evaluated for overall response rate and toxicities.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x